X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209697
https://www.reuters.com/business/healthcare-pharmaceuticals/merck-kgaa-says-ms-drug-fails-late-stage-trials-2023-12-05/
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-reports-rs-403-crore-loss-in-q4fy23/articleshow/100363533.cms
https://www.europeanpharmaceuticalreview.com/news/177879/stem-cell-transplants-may-slow-disability-progression-in-ms/
https://www.ema.europa.eu/en/documents/overview/teriflunomide-accord-epar-medicine-overview_en.pdf
https://tiefenbachergroup.com/2022/06/01/new-market-launch-tiefenbacher-pharmaceuticals-successfully-launches-first-generic-version-of-the-multiple-sclerosis-medicine-teriflunomide-in-canada/
https://www.apotex.com/global/about-us/press-center/2022/05/17/apotex-launches-affordable-generic-option-to-treat-relapsing-remitting-multiple-sclerosis#:~:text=Press%20Center&text=Toronto%2C%20ON%2C%20May%2017%2C,remitting%20multiple%20sclerosis%20(RRMS).
https://farmabios.com/de/2021/10/06/us-fda-approval-for-teriflunomide-it-2-2/
https://www.prnewswire.com/news-releases/breckenridge-announces-approval-of-its-anda-for-teriflunomide-tablets-generic-for-aubagio-301387953.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209583
http://www.pharmatimes.com/news/ec_approves_sanofis_aubagio_for_paediatric_ms_patients_1371902
https://www.globenewswire.com/news-release/2021/06/18/2249701/0/en/European-Commission-approves-Aubagio-teriflunomide-as-the-first-oral-MS-therapy-for-first-line-treatment-of-children-and-adolescents-living-with-relapsing-remitting-multiple-sclero.html
https://www.globenewswire.com/news-release/2021/06/18/2249806/0/en/TG-Therapeutics-Announces-Presentation-of-Data-from-the-ULTIMATE-I-II-Phase-3-Trials-of-Ublituximab-in-Multiple-Sclerosis-at-7th-Congress-of-the-European-Academy-of-Neurology.html
http://www.pharmatimes.com/news/tg_therapeutics_ublituximab_tops_sanofis_aubagio_in_ms_trial_1367393
https://www.fiercepharma.com/pharma/generic-catch-22-novartis-sandoz-sues-fda-over-sanofi-blockbuster-s-unlawful-exclusivity
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209677
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209677
https://www.fiercepharma.com/pharma/novartis-repurposed-leukemia-drug-tops-sanofi-s-aubagio-ms-study-weeks-ahead-fda-verdict
https://endpts.com/jj-pitches-their-s1p1-ms-drug-into-the-regulatory-ring-as-the-competition-heats-up-fast/
http://www.pmlive.com/pharma_news/j_and_j_eyes_us_approval_for_ms_drug_ponesimod_1329680
https://www.fiercepharma.com/pharma/ectrims-novartis-reinvented-leukemia-drug-bests-sanofi-s-aubagio-slashing-ms-relapses
https://endpts.com/jj-phiii-data-promise-drug-launch-into-crowded-ms-market/
https://www.reuters.com/article/us-novartis-ofatumumab/novartis-ms-drug-cuts-relapse-rate-by-half-compared-to-sanofi-medicine-idUSKCN1VY1EY?feedType=RSS&feedName=healthNews
https://www.fiercebiotech.com/biotech/j-j-s-multiple-sclerosis-med-tops-sanofi-s-aubagio-at-reducing-relapse-fatigue
https://www.clinicaltrialsarena.com/news/novartis-ofatumumab-phase-iii/
https://www.fiercepharma.com/pharma/novartis-repurposed-cancer-drug-arzerra-outpaces-sanofi-s-aubagio-multiple-sclerosis-trial
http://www.pharmafile.com/news/526046/ms-drug-boosts-effectiveness-cancer-therapy-treating-glioblastoma-study-shows
http://www.pharmatimes.com/news/janssens_ponesimod_holds_up_against_aubagio_in_late-stage_trial_1295491
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209572
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209710
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209668
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209601
https://www.dnaindia.com/business/report-glenmark-gets-usfda-nod-for-multiple-sclerosis-medication-2686304
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209638
https://www.fiercepharma.com/pharma/can-sanofi-s-new-long-term-lemtrada-amp-up-sales-a-crowded-ms-field
https://www.businesswire.com/news/home/20181010005160/en/Sanofi-presents-new-data-Aubagio%C2%AE-teriflunomide
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209613
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209700
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209555
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209549
https://www.statnews.com/pharmalot/2018/05/30/sanofi-subpoena-feds-charities/
http://www.fiercepharma.com/pharma/lawmakers-dig-into-skyrocketing-ms-costs-probe-into-7-drugmakers
http://www.businesswire.com/news/home/20170425005095/en/Data-Suggest-Positive-Effects-Sanofi-Genzyme%E2%80%99s-Aubagio%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
http://www.fiercepharma.com/marketing/oral-drugs-nab-lead-competitive-ms-market-but-for-how-long
http://www.prnewswire.com/news-releases/impax-confirms-patent-challenge-relating-to-generic-aubagio-teriflunomide-tablets-14-mg-300387031.html
Market Place
Share 
